Company Overview and News

 
PRI / Primerica, Inc. AMENDMENT NO. 1 TO DEF 14A

2018-04-13 sec.gov
AMENDMENT NO. 1 TO DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
Upvote Downvote

 
PRI / Primerica, Inc. DEFA14A

2018-04-13 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
Upvote Downvote

 
PRI / Primerica, Inc. DEF 14A

2018-04-05 sec.gov
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
PRI / Primerica, Inc. DEFA14A

2018-04-05 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
Upvote Downvote

 
4 Best Insurance Stocks to Buy After Fed Rate Hike

2018-03-22 investorplace
The first rate hike for 2018 comes as expected. With the latest raise of 25 basis points at the recently concluded FOMC meeting, the interest rate now stands at 1.50-1.75%. The decision was unanimously favored by all eight members of the regulatory body.
Upvote Downvote

 
Fed Hikes Rate, Upbeat Economic Data: 4 Best Insurers to Add

2018-03-22 zacks
The first rate hike for 2018 comes as expected. With the latest raise of 25 basis points at the recently concluded FOMC meeting, the interest rate now stands at 1.50-1.75%. The decision was unanimously favored by all eight members of the regulatory body. Jerome Powell for the first time addressed the meeting as Fed chairman after Janet Yellen stepped down and the current chairperson was sworn in late February.
Upvote Downvote

 
Powell May Commence Innings With a Rate Hike: 4 Value Picks

2018-03-21 zacks
All eyes are set on the outcome of the Federal Reserve’s meeting being held under the newly-elected chairman Jerome Powell, and if you have been following the tide, the Fed leader is likely to commence his innings with a hike in the interest rate. In all likelihood, the policy makers may raise the benchmark interest rate by a quarter percentage point for the first time this year to a range of 1.5-1.
Upvote Downvote

 
Zacks.com featured highlights include: Huntington Ingalls, Primerica, EMCOR, CBRE and Arrow

2018-03-20 zacks
Chicago, IL – March 20, 2018 - Stocks in this week’s article Huntington Ingalls Industries, Inc. (HII - Free Report) , Primerica, Inc. (PRI - Free Report) , EMCOR Group, Inc. (EME - Free Report) , CBRE Group, Inc. (CBG - Free Report) and Arrow Electronics, Inc. (ARW - Free Report) .
Upvote Downvote

 
7 Reasons Why Reinsurance Group (RGA) is Tailor-Made for You

2018-03-19 zacks
Reinsurance Group of America, Incorporated (RGA - Free Report) is an insurance holding company, primarily engaged in traditional individual and group life, asset-intensive, critical illness and financial reinsurance. This Zacks Rank #2 (Buy) life insurer remains a promising stock, backed by several growth prospects. Also, the company is part of the Life Insurance industry, falling in the top 12% bracket of the Zacks Industry Rank.
Upvote Downvote

 
These 5 Stocks Flaunt Attractive Interest Coverage Ratio

2018-03-19 zacks
You can simply arrive at a decision to Buy or Sell a particular stock by looking at its sales and earnings numbers. But such a strategy does not always guarantee superior returns. A critical analysis of the company’s financial background is always required for a better investment decision.
Upvote Downvote

 
6 Reasons Why You Should Hold on to Sun Life (SLF) Stock

2018-03-15 zacks
Sun Life Financial Inc. (SLF - Free Report) provides protection and wealth management products and services to individual and group customers worldwide. The Zacks Rank #3 (Hold) stock is the third largest insurer in Canada. The stock’s Zacks Consensus Estimate for both current and next-year earnings has been revised a cent upward over the last 60 days. While the consensus mark for 2018 moved north by 7.
Upvote Downvote

 
6 Reasons Why You Should Hold Torchmark in Your Portfolio

2018-03-14 zacks
Torchmark Corporation (TMK - Free Report) provides annuities, whole and term-life insurance, accidental death insurance, health insurance, Medicare supplements and long-term healthcare policies. The stock’s Zacks Consensus Estimate for both current and next-year earnings has been revised a cent upward over the last 60 days. While 2018 estimates moved north by 5.6%, consensus mark for 2019 moved up 0.
Upvote Downvote

 
4 Best Bets to Invest in Top-Ranked Life Insurance Industry

2018-03-09 zacks
The insurance industry seems well-poised for growth on the back of favorable operating conditions. Life insurers largely benefit from an improving rate environment owing to sensitivity to interest rates. The Fed kept its promise of three interest rate hikes in 2017 and announced three more in 2018 as well as two in 2019. These moves reflect President Trump’s bias for higher interest rates and the central bank’s confidence in improving U.
Upvote Downvote

 
PRI / Primerica, Inc. 10-K (Annual Report)

2018-02-26 sec.gov
pri-10k_20171231.htm
Upvote Downvote

 
Tracking Ruane, Cunniff, & Goldfarb's Portfolio - Q4 2017 Update

2018-02-26 seekingalpha
Ruane, Cunniff, & Goldfarb’s 13F portfolio value increased ~7% from $11.42B to $12.20B. The number of positions decreased from 69 to 66.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 74164M108